29 results on '"Galluppi GR"'
Search Results
2. Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
- Author
-
Hopkins SC, Toongsuwan S, Corriveau TJ, Watanabe T, Tsushima Y, Asada T, Lew R, Shi L, Zann V, Snowden TJ, van der Graaf PH, Darpo B, Searle GE, Rabiner EA, Wilding I, Szabo ST, Galluppi GR, and Koblan KS
- Subjects
- Humans, Animals, Male, Adult, Drug Development methods, Models, Biological, Female, Drug Discovery, Amisulpride administration & dosage, Amisulpride pharmacokinetics, Delayed-Action Preparations, Therapeutic Equivalency, Brain metabolism, Receptors, Dopamine D2 metabolism
- Abstract
Nonracemic amisulpride (SEP-4199) is an investigational 85:15 ratio of aramisulpride to esamisulpride and currently in clinical trials for the treatment of bipolar depression. During testing of SEP-4199, a pharmacokinetic/pharmacodynamic (PK/PD) disconnect was discovered that prompted the development of a controlled-release (CR) formulation with improved therapeutic index for QT prolongation. Observations that supported the development of a CR formulation included (i) plasma concentrations of amisulpride enantiomers were cleared within 24-hours, but brain dopamine D2 receptor (D2R) occupancies, although achieving stable levels during this time, required 5 days to return to baseline; (ii) nonracemic amisulpride administered to non-human primates produced significantly greater D2R occupancies during a gradual 6-hour administration compared with a single bolus; (iii) concentration-occupancy curves were left-shifted in humans when nonracemic amisulpride was gradually administered over 3 and 6 hours compared with immediate delivery; (iv) CR solid oral dose formulations of nonracemic amisulpride were able to slow drug dissolution in vitro and reduce peak plasma exposures in vivo in human subjects. By mathematically solving for a drug distribution step into an effect compartment, and for binding to target receptors, the discovery of a novel PK/PD model (termed here as Distribution Model) accounted for hysteresis between plasma and brain, a lack of receptor saturation, and an absence of accumulation of drug occupancy with daily doses. The PK/PD disconnect solved by the Distribution Model provided model-informed drug development to continue in Phase III using the non-bioequivalent CR formulation with diminished QT prolongation as dose-equivalent to the immediate release (IR) formulation utilized in Phase II., (© 2024 Sumitomo Pharma America, Inc. Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
3. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
- Author
-
Galluppi GR, Ahamadi M, Bhattacharya S, Budha N, Gheyas F, Li CC, Chen Y, Dosne AG, Kristensen NR, Magee M, Samtani MN, Sinha V, Taskar K, Upreti VV, Yang J, and Cook J
- Subjects
- United States, Humans, Pilot Projects, Drug Approval, United States Food and Drug Administration, Drug Development legislation & jurisprudence, Drug Development methods, Drug Industry legislation & jurisprudence
- Abstract
A recent industry perspective published in this journal describes the benefits received by drug companies from participation in the MIDD Pilot Program. Along with the primary objectives of supporting good decision-making in drug development, there were substantial savings in time and development costs. Furthermore, many sponsors reported qualitative benefits such as new learnings and clarity on MIDD strategies and methodology that could be applied to other development programs. Based on the success of the Pilot Program, the FDA recently announced the continuation of the MIDD Paired Meeting Program as part of the Prescription Drug User Fee Act (PDUFA VII). In this report, we describe the collective experiences of industry participants in the MIDD Program to date, including all aspects of the process from meeting request submission to follow-up actions. The purpose is to provide future participants with information to optimize the value of the MIDD Program., (© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
4. Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
- Author
-
Xiao G, Tsukada H, Chen YL, Shi L, Hopkins SC, and Galluppi GR
- Subjects
- Adult, Humans, Chromatography, Liquid, Cross-Over Studies, Drug Interactions genetics, Single-Blind Method, Tandem Mass Spectrometry, Organic Cation Transporter 2 drug effects, Metformin therapeutic use, Metformin pharmacology, Pyrans, Schizophrenia drug therapy
- Abstract
Ulotaront (SEP-363856) is a TAAR1 agonist, with 5-HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2-specific inhibitor with IC
50 of 1.27 μM. The primary objective of this study is to determine if a single dose of ulotaront affects the PK of metformin, an index substrate of OCT2, in subjects with schizophrenia. In a randomized, single-blind, 2-period crossover study, 25 adults with schizophrenia received a single dose of metformin-HCl 850 mg (approximately 663 mg metformin) with and without coadministration of 100 mg ulotaront. The plasma samples were analyzed by fully validated LC-MS/MS methods. The primary PK endpoints for metformin were AUCinf , AUClast , Cmax , and tmax . The highest-anticipated clinical dose of ulotaront (100 mg) had no statistically significant effect on the PK of a single dose of metformin based on Cmax and AUCinf . Geometric least squares mean ratios were 89.98% and 110.63%, respectively, with the 90% confidential interval (CI) for each parameter contained within 80%-125%. Median tmax was comparable across the treatments. Ulotaront does not act as a perpetrator of OCT2-mediated DDI against metformin. Co-administration of ulotaront is not expected to require dose adjustment of metformin or other drugs cleared by OCT2., (© 2024 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
5. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
- Author
-
Tsukada H, Chen YL, Xiao G, Lennek L, Milanovic SM, Worden M, Polhamus DG, Chiu YY, Hopkins SC, and Galluppi GR
- Subjects
- Humans, Healthy Volunteers, Cytochrome P-450 CYP2D6 Inhibitors pharmacokinetics, Drug Interactions, Enzyme Inhibitors, Area Under Curve, Cytochrome P-450 CYP2D6 metabolism, Paroxetine adverse effects
- Abstract
Background: Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT
1A ) receptors in phase III clinical development for the treatment of schizophrenia., Objective: This study aimed to investigate the effect of paroxetine, a strong cytochrome P450 (CYP) 2D6 inhibitor, on ulotaront pharmacokinetics (PK) in healthy volunteers., Methods: Subjects received a single oral dose of 25 mg ulotaront on Day 1 and an oral dose of 20 mg paroxetine once daily from Days 5 to 10 to achieve steady-state plasma paroxetine levels. On Day 11, subjects received another single oral dose of 25 mg ulotaront, with continued daily oral dosing of 20 mg paroxetine from Days 11 to 14. All 24 subjects were CYP2D6 normal metabolizers., Results: Coadministration of paroxetine increased ulotaront maximum observed plasma concentration (Cmax ) and area under the plasma concentration-time curve from time zero to infinity (AUC∞ ) by 31% and 72%, respectively, and decreased ulotaront apparent clearance (CL/F) by approximately 42%. While coadministration of paroxetine increased AUC∞ of active but minor metabolite SEP-363854 by 32%, it had no effect on SEP-363854 Cmax , or on SEP-363854 to the ulotaront AUC from time zero to the last quantifiable concentration (AUClast ) ratio. Based on the acceptable adverse event profile of ulotaront across previous phase II studies, the increase in ulotaront exposure is unlikely to be clinically meaningful., Conclusions: Weak drug-drug interactions were observed between ulotaront and the strong CYP2D6 inhibitor paroxetine; however, dose adjustment as a precondition when ulotaront is coadministered with strong CYP2D6 inhibitors or administered to CYP2D6 poor metabolizers should not be necessary., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
6. Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.
- Author
-
Chen YL, Tsukada H, Milanovic S, Shi L, Li Y, Mao Y, Koblan KS, and Galluppi GR
- Abstract
Introduction: Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT
1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotaront and the food effect (FE) on pharmacokinetics (PK) of tablet form in healthy adult human subjects., Methods: The BE study applied an open-label two-period crossover design in 24 healthy volunteers. Subjects were randomly assigned (1:1) to dosing sequence AB or BA (A, 25 mg ulotaront tablet; B, 25 mg ulotaront capsule). The FE study also used an open-label randomized two-period crossover design in 20 healthy volunteers. Subjects were fasted overnight then randomly assigned (1:1) to dosing sequence AB or BA (A, fasted condition; B, fed condition). Dosing periods were separated by 1 week for both studies. Serial plasma samples from each period were collected and analyzed by LC-MS/MS. PK parameters were calculated using Phoenix WinNonlin® software., Results: For the BE study, geometric mean ulotaront Cmax values were 93.28 and 86.98 ng/mL for tablet and capsule, respectively. Cmax ratio was 107.25% (90% CI 101.84-112.94%). Geometric mean ulotaront area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞ ) values were 868.8 and 829.3 ng·h/mL for tablet and capsule, respectively. AUC0-∞ ratio was 104.76% (90% CI 100.68109.01%). For the FE study, geometric mean ulotaront Cmax was 157.89 and 157.95 ng/mL under fed and fasted conditions, respectively. Geometric mean ratio of Cmax was 99.96% (90% CI 94.48-105.77%). Geometric mean ulotaront AUC0-∞ was 1584.2 ng·h/mL fed and 1589.2 ng·h/mL fasted. Geometric mean ratio for AUC0-∞ was 99.69% (90% CI 95.02-104.58%). There was a delay in tmax (median difference 1.47 h) in the fed condition., Conclusions: The results showed geometric mean ratios and 90% CIs for both Cmax and AUC0-∞ for ulotaront were well within typical bioequivalence criteria of 80-125% for both the BE and FE studies, thereby confirming the bioequivalence of the two dosage forms and no significant food effect., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
7. A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
- Author
-
Tsukada H, Milanovic SM, Darpo B, Xue H, Xiong K, Tripp E, Lennek L, Worden M, Hopkins SC, and Galluppi GR
- Subjects
- Humans, Moxifloxacin, Cross-Over Studies, Electrocardiography, Double-Blind Method, Heart Rate, Dose-Response Relationship, Drug, Fluoroquinolones, Schizophrenia diagnosis, Schizophrenia drug therapy
- Abstract
This study (NCT04369391) evaluated the effects of ulotaront (SEP-363856), a novel trace amine-associated receptor 1 (TAAR1) agonist in development for schizophrenia, on electrocardiogram parameters. Study design was a randomized, single-dose, three-period crossover (ulotaront 150 mg, placebo, moxifloxacin 400 mg). Sixty subjects with schizophrenia completed all periods. Ulotaront had no clinically relevant effect on heart rate, PR interval, or QRS duration. In by-time-point analysis (secondary analysis), the upper bound of the two-sided 90% confidence interval for ΔΔQTcF (QT interval corrected for heart rate using Fridericia's formula) was below 10 ms at all time points for ulotaront. In concentration-QTc analysis (primary analysis), a linear mixed-effects model with ulotaront and its major metabolite SEP-383103 was selected as the primary model based on prespecified criteria. Effect on ∆∆QTcF exceeding 10 ms can be excluded within observed ranges of ulotaront and SEP-383103 plasma concentrations up to ~574 and ~272 ng/mL, respectively. The upper bound of 90% CI for ΔΔQTcF can be predicted to be below 10 ms at the highest anticipated clinical exposure, currently defined as steady-state mean C
max at ulotaront 100 mg/day in CYP2D6 poor metabolizers, ~416 and ~211 ng/mL for ulotaront and SEP-383103, respectively. Assay sensitivity was demonstrated by the QTc effect caused by moxifloxacin. In conclusion, ulotaront is unlikely to cause clinically relevant QTc prolongation in patients with schizophrenia at the anticipated maximum therapeutic dose., (© 2023 Sunovion Pharmacueticals Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)- Published
- 2023
- Full Text
- View/download PDF
8. ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.
- Author
-
Darpo B, Borin M, Ferber G, Galluppi GR, Hopkins SC, Landry I, Lo A, Rege B, Reyderman L, Sun L, Watanabe T, Xue H, and Yasuda S
- Subjects
- Humans, Electrocardiography, Risk Assessment, Pharmacology, Clinical, Long QT Syndrome chemically induced
- Abstract
The International Conference on Harmonization (ICH) E14 document was revised in 2015 to allow concentration-corrected QT interval (C-QTc) analysis to be applied to data from early clinical pharmacology studies to exclude a small drug-induced effect on QTc. Provided sufficiently high concentrations of the drug are obtained in the first-in-human (FIH) study, this approach can be used to obviate the need for a designated thorough QT (TQT) study. The E14 revision has resulted in a steady reduction in the number of TQT studies and an increased use of FIH studies to evaluate electrocardiogram (ECG) effects of drugs in development. In this review, five examples from different sponsors are shared in which C-QTc analysis was performed on data from FIH studies. Case 1 illustrates a clearly negative C-QTc evaluation, despite observations of QTc prolongation at high concentrations in nonclinical studies. In case 2 C-QTc analysis of FIH data was performed prior to full pharmacokinetic characterization in patients, and the role of nonclinical assays in an integrated risk assessment is discussed. Case 3 illustrates a positive clinical C-QTc relationship, despite negative nonclinical assays. Case 4 demonstrates a strategy for characterizing the C-QTc relationship for a nonracemic therapy and formulation optimization, and case 5 highlights an approach to perform a preliminary C-QTc analysis early in development and postpone the definitive analysis until proof of efficacy is demonstrated. The strategy of collecting and storing ECG data from FIH studies to enable an informed decision on whether and when to apply C-QTc analysis to obviate the need for a TQT study is described., (© 2022 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.)
- Published
- 2022
- Full Text
- View/download PDF
9. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT 1A Receptor Agonist for the Treatment of Schizophrenia.
- Author
-
Xiao G, Chen YL, Dedic N, Xie L, Koblan KS, and Galluppi GR
- Subjects
- Animals, Cytochrome P-450 CYP2D6 metabolism, Cytochrome P-450 Enzyme System metabolism, Mice, Microsomes, Liver metabolism, NADP metabolism, NADP pharmacology, Pharmaceutical Preparations metabolism, Rats, Receptor, Serotonin, 5-HT1A metabolism, Schizophrenia drug therapy
- Abstract
Purpose: Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT
1A agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK, and to evaluate the DDI potential of ulotaront and its major metabolite SEP-383103., Methods: Solubility, permeability, plasma protein binding, CYP inhibition and induction, transporter inhibition and uptake studies were conducted in vitro. Phenotyping studies were conducted using recombinant human CYPs and FMOs, human liver microsomes and human liver homogenates. Preclinical plasma and brain pharmacokinetics were determined after a single intraperitoneal, intravenous, and oral administration of ulotaront., Results: Ulotaront is a compound of high solubility, high permeability, and low binding to plasma proteins. Ulotaront metabolism is mediated via both NADPH-dependent and NADPH-independent pathways, with CYP2D6 as the major metabolizing enzyme. Ulotaront is an inducer of CYP2B6, and an inhibitor of CYP2D6, OCT1 and OCT2, while SEP-383103 is neither a CYP inducer nor a potent inhibitor of CYPs and human transporters. Ulotaront exhibits rapid absorption, greater than 70% bioavailability, approximately 3.5 L/kg volume of distribution, 1.5-4 h half-life, 12-43 ml/min/kg clearance, and good penetration across the blood-brain barrier in preclinical species., Conclusions: Ulotaront has been designated as a BCS1 compound by US FDA. The ability of ulotaront to penetrate the blood-brain barrier for CNS targeting has been demonstrated in mice and rats. The potential for ulotaront and SEP-383103 to act as perpetrators of CYP and transporter-mediated DDIs is predicted to be remote., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
10. A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study.
- Author
-
Chen YL, Shi Y, LaFayette A, Shi L, Koblan KS, and Galluppi GR
- Subjects
- Chromatography, Liquid, Humans, Pyrans, Reproducibility of Results, Plasma, Tandem Mass Spectrometry
- Abstract
Ulotaront (SEP-363856) is a novel non-D2-receptor-binding agent under development for the treatment of patients with schizophrenia. A highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with lower limit of quantitation of 0.0200 ng/mL (i.e. 20.0 pg/mL) was successfully developed and validated for the simultaneous quantitation of ulotaront and its N-desmethyl metabolite (M11A) in human plasma. Plasma samples were extracted by solid phase extraction with Oasis MCX 96-well plate, followed by a reversed phase LC separation coupled with MS/MS detection in positive mode (m/z 184.1 → 135.0 for ulotaront and 170.1 → 135.0 for M11A). Stable isotope-labeled compounds SEP-363856-d
3 and M11A-d4 were used as internal standards (IS) for corresponding analytes. The validated calibration curve range was 0.0200-20.0 ng/mL for both analytes using a 0.200 mL plasma. Extraction recoveries were found to be 75.7% and 75.1% for ulotaront and IS1, and 82.7% and 83.9% for M11A and IS2, respectively. Frozen plasma samples were confirmed to be stable for up to 730 days at both -20 °C and -70 °C. The validated method has been successfully used to evaluate the pharmacokinetics (PK) of ulotaront and M11A in clinical studies. The application to the first-in-human PK study (single ascending dose) presented in this work demonstrated that ulotaront exhibited near dose proportionality for both Cmax (maximum concentration) and AUC (area under the curve) over the dose range from 5 to 125 mg. M11A was found as a minor metabolite with an exposure of about 2-3% of the parent compound., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
11. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
- Author
-
Galluppi GR, Brar S, Caro L, Chen Y, Frey N, Grimm HP, Rudd DJ, Li CC, Magee M, Mukherjee A, Nagao L, Purohit VS, Roy A, Salem AH, Sinha V, Suleiman AA, Taskar KS, Upreti VV, Weber B, and Cook J
- Subjects
- Drug Approval legislation & jurisprudence, Drug Development legislation & jurisprudence, Drug Development methods, Drug Industry legislation & jurisprudence, Humans, Pilot Projects, United States, Drug Approval methods, Drug Design, Drug Industry methods, United States Food and Drug Administration legislation & jurisprudence
- Published
- 2021
- Full Text
- View/download PDF
12. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
- Author
-
Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, and Koblan KS
- Subjects
- Adolescent, Adult, Female, Humans, Male, Middle Aged, Young Adult, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Healthy Volunteers, Receptor, Serotonin, 5-HT1A, Pyrans pharmacokinetics, Pyrans therapeutic use, Receptors, G-Protein-Coupled agonists, Schizophrenia drug therapy, Serotonin 5-HT1 Receptor Agonists pharmacokinetics, Serotonin 5-HT1 Receptor Agonists therapeutic use
- Abstract
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 agonist with 5-HT
1A agonist activity in phase III development for the treatment of schizophrenia. The efficacy of ulotaront is not mediated by blockade of D2 or 5-HT2A receptors. The aim of this study was to evaluate the population pharmacokinetics (PopPKs) of ulotaront in adult subjects using pooled data from seven phase I studies, one phase II acute study, and one 6-month extension study. Single and multiple (up to 7 days) oral doses (5-150 mg/day) were studied in both healthy adult subjects (with intensive serial plasma sampling) and adult patients with schizophrenia (some with intensive and some with sparse plasma sampling). Ulotaront was well-absorbed and exhibited dose-proportionality in doses ranging from 10 to 100 mg, in mean maximum concentration, area under the concentration-time curve, and minimum concentration. Moderate interindividual variability was observed in concentration-time profiles. The estimated median time to maximal concentration was 2.8 h and the median effective half-life was 7 h, corresponding to an exposure accumulation ratio of 1.10 at steady-state with daily dosing. There was no indication of time-dependent changes in PKs after up to 12 weeks of daily dose administration. No clinically meaningful effects on ulotaront PK parameters were observed based on race, age, sex, formulation (capsule or tablet), or clinical status (healthy volunteer vs. patient with schizophrenia); body weight was the only meaningful covariate., (© 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)- Published
- 2021
- Full Text
- View/download PDF
13. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.
- Author
-
Galluppi GR, Wisniacki N, and Stebbins C
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized pharmacokinetics, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Neutralizing pharmacology, Asian People, Broadly Neutralizing Antibodies, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Humans, Infusions, Intravenous, Male, Nonlinear Dynamics, White People, Young Adult, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Neutralizing administration & dosage, Arthritis, Rheumatoid drug therapy, Cytokine TWEAK antagonists & inhibitors
- Abstract
Aims: Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is implicated in the pathogenesis of lupus nephritis. This study evaluated the pharmacokinetics, using the population approach, and pharmacodynamics of BIIB023, an anti-TWEAK monoclonal antibody, in healthy Chinese, Japanese and Caucasian volunteers., Methods: In this single-dose, randomized, double-blind, phase 1 study of BIIB023 in healthy volunteers, BIIB023 was administered by intravenous infusion (3 or 20 mg kg(-1) ) on Day 1; follow-up occurred through Day 71. BIIB023 serum concentration was measured using a validated enzyme-linked immunosorbent assay; BIIB023 concentration-time data were subjected to noncompartmental analysis. Population pharmacokinetic analysis was performed using data from this study and a prior phase 1 study of BIIB023 in subjects with rheumatoid arthritis. Soluble TWEAK and, Tweak: BIIB023 complex were evaluated., Results: There were no differences in BIIB023 pharmacokinetics requiring dose adjustment among the three ethnic groups or between healthy volunteers and arthritis patients. BIIB023 central compartment volume (3050 ml) and clearance (7.42 ml h(-1) ) were comparable to those observed for other monoclonal antibody drugs. BIIB023 serum exposure increased in a dose-dependent manner in all groups, but not in direct proportion to dose level; at concentrations below ~10 μg ml(-1) , nonlinear clearance was observed. Soluble TWEAK levels decreased to below the level of quantitation after BIIB023 treatment, with concomitant changes in, Tweak: BIIB023 complex levels., Conclusions: No clinically meaningful differences were observed in BIIB023 pharmacokinetic and pharmacodynamic properties in healthy Chinese, Japanese and Caucasian volunteers; pharmacodynamic measures suggested target engagement. TWEAK may be an attractive therapeutic target for lupus nephritis treatment., (© 2016 The British Pharmacological Society.)
- Published
- 2016
- Full Text
- View/download PDF
14. Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.
- Author
-
Rogge MC, Liu Y, and Galluppi GR
- Subjects
- Adjuvants, Immunologic pharmacokinetics, Adjuvants, Immunologic pharmacology, Adult, Female, Humans, Injections, Intramuscular, Interferon beta-1a, Interferon-beta pharmacokinetics, Interferon-beta pharmacology, Male, Models, Biological, Young Adult, Adjuvants, Immunologic administration & dosage, Asian People, Interferon-beta administration & dosage
- Abstract
Interferon beta-1a (IFNβ-1a) is a first-line therapy for relapsing multiple sclerosis when administered as 30 mcg intramuscularly (IM) once weekly. This endogenous cytokine displays pharmacokinetic (PK) attributes consistent with a glycoprotein of 20-kDa molecular weight that is administered IM. In this study, 24 healthy Chinese subjects (11 male, 13 female) each received 4 once-weekly 60-mcg IM doses of IFNβ-1a. Serial blood samples were drawn for PK and pharmacodynamic (PD) assessments following the first and last dose of drug. Results were compared with historical data from a recent PK/PD assessment conducted in non-Chinese subjects. Noncompartmental analysis revealed that no meaningful differences in either IFNβ-1a exposure or response were apparent between the Chinese and non-Chinese populations. Thus, it was concluded that no adjustment in dose regimen is warranted for future assessments of safety and efficacy in multiple sclerosis patients of Chinese origin., (© 2014, The American College of Clinical Pharmacology.)
- Published
- 2014
- Full Text
- View/download PDF
15. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
- Author
-
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, and Leong S
- Subjects
- Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal blood, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal, Humanized, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Antineoplastic Agents pharmacokinetics, Drug Resistance, Neoplasm, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local drug therapy, Neoplasms blood, Receptor, IGF Type 1 blood, Receptor, IGF Type 1 immunology, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents administration & dosage, Neoplasms drug therapy, Receptor, IGF Type 1 antagonists & inhibitors
- Abstract
Purpose: The IGF-1R signaling pathway has been implicated in multiple cancers as important for cell survival, proliferation, invasion and metastasis. BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R. Unlike other anti-IGF1R antibodies, BIIB022 has no effector functions. Additionally, inhibition is via an allosteric rather than competitive mechanism, which further differentiates this antibody from others. We sought to determine the safety and tolerability of BIIB022 and determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of this antibody., Methods: A multi-institutional phase I study evaluated the safety of escalating doses of BIIB022 given IV q3wk until progression or unacceptable toxicity in patients with advanced solid tumors. Five sequential BIIB022 dose cohorts were evaluated using a standard 3 + 3 dose-escalation design (1.5, 5. 10, 20, 30 mg/kg); 10 additional patients were treated at the recommended phase 2 dose., Results: 34 patients were treated. Toxicities were manageable and mostly low grade; grade 3-4 hyperglycemia was not observed. No RECIST responses were observed, although three patients had metabolic responses associated with prolonged stable disease. The PK of BIIB022 was nearly linear in the dose range from 10 to 30 mg/kg, with some nonlinearity at lower doses (1.5-5.0 mg/kg), likely due to target-mediated drug disposition of BIIB022 at low serum concentrations. PD analyses showed decrease in IGF-1R levels on leucocytes, with stable serum values of IGF-1 and IGF-2., Conclusions: BIIB022 can be safely given at 30 mg/kg IV every 3 weeks with preliminary evidence of biological activity in selected patients.
- Published
- 2014
- Full Text
- View/download PDF
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
- Author
-
Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, and Burkly LC
- Subjects
- Administration, Intravenous, Adolescent, Adult, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Neutralizing, Antirheumatic Agents administration & dosage, Antirheumatic Agents adverse effects, Antirheumatic Agents pharmacokinetics, Broadly Neutralizing Antibodies, Cytokine TWEAK, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inflammation drug therapy, Methotrexate pharmacokinetics, Methotrexate therapeutic use, Middle Aged, Receptors, Tumor Necrosis Factor metabolism, TWEAK Receptor, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factors immunology, Tumor Necrosis Factors metabolism, Young Adult, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized pharmacokinetics, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Tumor Necrosis Factor Inhibitors
- Abstract
Background: Persistent upregulation of signaling by cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK) through its receptor fibroblast growth factor-inducible molecule-14 (Fn14) promotes chronic inflammation and tissue destruction., Objective: The aim of this study was to explore the safety and tolerability of the TWEAK-blocking monoclonal antibody BIIB023 and determine its pharmacokinetics and effects on TWEAK pathway pharmacodynamic markers in rheumatoid arthritis (RA)., Methods: Phase I, first-in-human, 2-part, multicenter, double-blind, dose-escalation study. Patients were randomized to a single dose of BIIB023 (0.03-20 mg/kg) (n = 38) or placebo (n = 15) as an add-on to methotrexate. Three open-label cohorts of RA patients taking background disease-modifying antirheumatic drugs and stable tumor necrosis factor (TNF) inhibitor therapy (n = 12) received a single-dose of BIIB023 of 2, 10, or 20 mg/kg and were assessed over 70 days., Results: The incidence of treatment-emergent adverse events for the BIIB023 monotherapy cohorts and open-label cohorts of BIIB023 as add-on therapy to TNF inhibitors compared with placebo were 47% and 50% versus 33%, respectively. Serum exposure to BIIB023 increased in a dose-dependent manner from 0.03 to 20 mg/kg, but not in direct proportion to dose level. After administration, the time course of BIIB023 serum concentration was multiphasic and showed expedited elimination when levels decreased to < 10 µg/mL. Serum-soluble TWEAK levels were suppressed at all dose levels by 6 hours post-dose and recovered to baseline between days 7 and 28. A trend toward downward modulation of serum biomarkers of inflammatory response was suggested in monocyte chemoattractant protein 1, inducible protein 10, macrophage inflammatory protein 1β, and tissue inhibitor of metalloproteinase 1 in the BIIB023 group versus placebo., Conclusions: Single-dose BIIB023 showed a favorable safety and tolerability profile in RA. Suppression of serum-soluble TWEAK for ≤ 28 days was observed and downward trends in serum biomarkers suggested., (© 2013 Elsevier HS Journals, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
17. Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.
- Author
-
Morris DL, O'Neil SP, Devraj RV, Portanova JP, Gilles RW, Gross CJ, Curtiss SW, Komocsar WJ, Garner DS, Happa FA, Kraus LJ, Nikula KJ, Monahan JB, Selness SR, Galluppi GR, Shevlin KM, Kramer JA, Walker JK, Messing DM, Anderson DR, Mourey RJ, Whiteley LO, Daniels JS, Yang JZ, Rowlands PC, Alden CL, Davis JW 2nd, and Sagartz JE
- Subjects
- Animals, B-Lymphocytes metabolism, Blotting, Western, Cell Proliferation drug effects, Cells, Cultured, Colon drug effects, Colon pathology, Dogs, Female, Gastrointestinal Diseases pathology, Gastrointestinal Hemorrhage chemically induced, Humans, Immunohistochemistry, Intracellular Signaling Peptides and Proteins metabolism, Linear Models, Lymph Nodes drug effects, Lymph Nodes pathology, Lymphatic Diseases pathology, Macaca fascicularis, Male, Mice, Protein Serine-Threonine Kinases metabolism, Rats, Rats, Sprague-Dawley, Spleen cytology, Spleen metabolism, T-Lymphocytes metabolism, Toxicity Tests, Acute, p38 Mitogen-Activated Protein Kinases metabolism, Gastrointestinal Diseases chemically induced, Intracellular Signaling Peptides and Proteins antagonists & inhibitors, Lymphatic Diseases chemically induced, Protein Kinase Inhibitors toxicity, Protein Serine-Threonine Kinases antagonists & inhibitors, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors
- Abstract
Exposure to moderately selective p38alpha mitogen-activated protein kinase (MAPK) inhibitors in the Beagle dog results in an acute toxicity consisting of mild clinical signs (decreased activity, diarrhea, and fever), lymphoid necrosis and depletion in the gut-associated lymphoid tissue (GALT), mesenteric lymph nodes and spleen, and linear colonic and cecal mucosal hemorrhages. Lymphocyte apoptosis and necrosis in the GALT is the earliest and most prominent histopathologic change observed, followed temporally by neutrophilic infiltration and acute inflammation of the lymph nodes and spleen and multifocal mucosal epithelial necrosis and linear hemorrhages in the colon and cecum. These effects are not observed in the mouse, rat, or cynomolgus monkey. To further characterize the acute toxicity in the dog, a series of in vivo, in vitro, and immunohistochemical studies were conducted to determine the relationship between the lymphoid and gastrointestinal (GI) toxicity and p38 MAPK inhibition. Results of these studies demonstrate a direct correlation between p38alpha MAPK inhibition and the acute lymphoid and gastrointestinal toxicity in the dog. Similar effects were observed following exposure to inhibitors of MAPK-activated protein kinase-2 (MK2), further implicating the role of p38alpha MAPK signaling pathway inhibition in these effects. Based on these findings, the authors conclude that p38alpha MAPK inhibition results in acute lymphoid and GI toxicity in the dog and is unique among the species evaluated in these studies.
- Published
- 2010
- Full Text
- View/download PDF
18. Plasma protein binding in drug discovery and development.
- Author
-
Howard ML, Hill JJ, Galluppi GR, and McLean MA
- Subjects
- Biosensing Techniques methods, High-Throughput Screening Assays methods, Humans, Protein Binding, Blood Proteins metabolism, Drug Discovery methods, Pharmaceutical Preparations metabolism
- Abstract
This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited for measurement of compounds that are highly protein bound. The methods reviewed herein include the conventional techniques of equilibrium dialysis, ultrafiltration and ultracentrifugation, as well as some more novel approaches utilizing micropartitioning and biosensor-based analysis. Additional concepts that are discussed include plasma protein structure, enantioselective protein binding, drug displacement, the effect of patient demographics and disease states on free (unbound) drug levels, and the influence of protein binding on drug candidate pharmacokinetics and pharmacodynamics. Practical considerations pertaining to the evaluation of highly protein bound drug candidates are also highlighted.
- Published
- 2010
- Full Text
- View/download PDF
19. Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam).
- Author
-
Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, and Katre NV
- Subjects
- Animals, Capsules, Chromatography, Liquid, Drug Delivery Systems methods, Drug Stability, Granulocyte Colony-Stimulating Factor chemical synthesis, Granulocyte Colony-Stimulating Factor genetics, Humans, Interleukin-3 chemical synthesis, Interleukin-3 genetics, Rats, Recombinant Fusion Proteins, Recombinant Proteins, Time Factors, Triglycerides pharmacokinetics, Delayed-Action Preparations pharmacokinetics, Granulocyte Colony-Stimulating Factor agonists, Granulocyte Colony-Stimulating Factor pharmacokinetics, Interleukin-3 agonists, Interleukin-3 pharmacokinetics, Liposomes pharmacokinetics
- Abstract
Myelopoietins (MPO) are novel chimeric growth factors containing IL-3 and G-CSF receptor agonists that enhance the biological properties of both cytokines. These cytokines, like many therapeutic proteins, clear rapidly from circulation and must be administered daily to provide efficacy. Therefore, a controlled and sustained delivery system comprised of a biocompatible and biodegradable matrix, would offer important therapeutic advantages in the clinic, such as significantly reducing dose frequency and providing efficacy without toxicity. We report here the encapsulation of Leridistim (a protein from the MPO family) in multivesicular liposomes (DepoFoam) for sustained delivery, and demonstrate that a single injection of DepoFoam-encapsulated Leridistim results in elevated neutrophil counts for 10 days, in contrast to only 2 days for un-encapsulated Leridistim. Moreover, varying the lipid content of the DepoFoam matrix modulated the duration of elevated neutrophils from 2-3 to 9-10 days. The encapsulated Leridistim was released in vivo from the multivesicular liposomes in a uniform manner, consistent with its pharmacodynamic duration. Finally, a reproducible pharmacodynamic effect was observed with several batches of a DepoLeridistim formulation, indicating consistency of the manufacturing process of the DepoFoam delivery system. The capability of altering the release rates by varying the lipid composition provides maximum flexibility for controlled delivery of cytokine therapeutics.
- Published
- 2003
- Full Text
- View/download PDF
20. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.
- Author
-
Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, and Peck CC
- Subjects
- Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Approval, Drug Design, Pharmacokinetics, Pharmacology, Proteins therapeutic use
- Published
- 2001
- Full Text
- View/download PDF
21. Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta.
- Author
-
Seyedin SM, Thompson AY, Bentz H, Rosen DM, McPherson JM, Conti A, Siegel NR, Galluppi GR, and Piez KA
- Subjects
- Amino Acid Sequence, Animals, Bone and Bones, Cattle, Cell Division drug effects, Cell Line, Chromatography, High Pressure Liquid, Growth Substances, Proteins isolation & purification, Proteins pharmacology
- Abstract
Comparison of the sequence of the N-terminal 30 amino acids of cartilage-inducing factor-A (CIF-A) from bovine demineralized bone with the corresponding sequence of human transforming growth factor-beta (TGF-beta) revealed 100% identity. Furthermore, CIF-A stimulated normal rat kidney fibroblasts to become anchorage-independent and form colonies in soft agar (in the presence of epidermal growth factor) in a manner similar to TGF-beta. Similarly, TGF-beta from human platelets induced rat muscle mesenchymal cells to differentiate and synthesize cartilage-specific macromolecules in a manner equivalent to CIF-A. These data show that CIF-A and TGF-beta are closely related or identical molecules and that these factors may be involved in cell differentiation including cartilage formation as the first step in endochondral bone formation.
- Published
- 1986
22. Atriopeptins: a family of potent biologically active peptides derived from mammalian atria.
- Author
-
Geller DM, Currie MG, Wakitani K, Cole BR, Adams SP, Fok KF, Siegel NR, Eubanks SR, Galluppi GR, and Needleman P
- Subjects
- Amino Acid Sequence, Animals, Atrial Natriuretic Factor, Biological Assay, Chickens, Diuresis drug effects, Molecular Weight, Muscle Contraction drug effects, Muscle Proteins pharmacology, Muscle, Smooth physiology, Natriuresis drug effects, Rabbits, Rats, Structure-Activity Relationship, Heart Atria analysis, Muscle Proteins isolation & purification
- Abstract
Extracts of rat atria are potent stimulators of sodium and urine excretion, and relax vascular and intestinal smooth muscle preparations. The structures of six biologically active peptides obtained from atrial extracts are reported here. Ion exchange chromatography of a low molecular weight fraction obtained by gel filtration of atrial extracts produced two natriuretic fractions: the first induced relaxation of intestinal smooth muscle strips only, whereas the second also relaxed vascular strips as well. From the first fraction four pure biologically active peptides obtained by reverse phase HPLC have been sequenced: the 21 amino acid peptide, designated atriopeptin I, and three homologs (des- ser1 -, des- ser1 -ser2-, and des- ser21 - atriopeptin I). From the second fraction two pure biologically active peptides were obtained, which had C-terminal extensions of atriopeptin I: atriopeptins II (23 amino acid residues) and III (24 residues), having respectively phe-arg and phe-arg-tyr C-termini. These results suggest that this family of six peptides, sharing the same 17 membered ring formed by an internal cystine disulfide, is derived from a common high molecular weight precursor.
- Published
- 1984
- Full Text
- View/download PDF
23. Atriopeptins: bioactive peptides derived from mammalian cardiac atria.
- Author
-
Currie MG, Geller DM, Cole BR, Siegel NR, Fok KK, Adams SP, Eubanks SR, Galluppi GR, and Needleman P
- Subjects
- Animals, Atrial Natriuretic Factor analysis, Atrial Natriuretic Factor pharmacology, Biological Assay methods, Chickens, Chromatography, High Pressure Liquid, Diuresis drug effects, Heart Atria analysis, Molecular Weight, Muscle Relaxation drug effects, Muscle, Smooth, Vascular drug effects, Natriuresis drug effects, Rabbits, Rats, Rats, Inbred Strains, Rectum drug effects, Atrial Natriuretic Factor isolation & purification
- Abstract
Mammalian atria possess bioactive peptides that are natriuretic-diuretic and potent relaxants of vascular and nonvascular smooth muscle. Characterization of the biological activity of rat atrial extracts indicates two major peaks, having apparent molecular weight of 20,000-30,000 (atriopeptigen) and less than 10,000 (atriopeptins). The amino acid sequence of atriopeptins I, II and III have been determined, and it has been found that their structures are only slightly different. Atriopeptin I (twenty-one amino acid residues); ser-ser-cys-phe-gly-gly-arg-ile-asp-arg-ile-gly-ala-gln-ser-gly-leu-gly- cys- asn-ser) relaxes intestinal but not vascular smooth muscle strips, and is natriuretic. Atriopeptins II and III (23 and 24 residues; the 21-sequence of I with the addition of phe-arg or phe-arg-tyr at the C-terminus, respectively) relax intestinal and vascular smooth muscle strips and are potent natriuretics. Since atriopeptigen and the atriopeptins exhibit similar biological effects the possibility of a precursor-product relationship was tested. Mild proteolytic digestion (1IU/ml trypsin) of atriopeptigen activates this peptide and reduces its apparent molecular weight. Examination of whether the atria of Krebs perfused isolated hearts released the bioactive atrial peptides revealed the presence in the cardiac effluent of a trypsin-labile substance that was natriuretic-diuretic and a smooth muscle relaxant. To determine which form of the atrial peptide (e.g. atriopeptigen or atriopeptin) is released by the atria the cardiac effluents were concentrated and partially purified. The cardiac effluent contained a substance(s) similar to atriopeptin, but did not appear to possess the less-active high molecular weight peptide, atriopeptigen.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1984
24. ATP-induced changes in the binding of RNA synthesis termination protein Rho to RNA.
- Author
-
Galluppi GR and Richardson JP
- Subjects
- Adenosine Triphosphate, Binding Sites, Kinetics, Models, Biological, Poly C, Poly U, Protein Binding, Ribonucleases metabolism, Escherichia coli metabolism, RNA, Bacterial biosynthesis, Rho Factor, Transcription Factors
- Published
- 1980
- Full Text
- View/download PDF
25. DNA synthesis and applications to molecular biology.
- Author
-
Adams SP and Galluppi GR
- Subjects
- Animals, Cloning, Molecular, Codon, Gene Expression Regulation, Genes, Synthetic, Genetic Vectors, Humans, Mutation, Nucleic Acid Hybridization, Oligonucleotides metabolism, Protein Biosynthesis, Ribosomes metabolism, Transcription, Genetic, DNA biosynthesis
- Published
- 1986
- Full Text
- View/download PDF
26. Expression of bacterial genes in plant cells.
- Author
-
Fraley RT, Rogers SG, Horsch RB, Sanders PR, Flick JS, Adams SP, Bittner ML, Brand LA, Fink CL, Fry JS, Galluppi GR, Goldberg SB, Hoffmann NL, and Woo SC
- Subjects
- Aminoglycosides pharmacology, Cells, Cultured, Cloning, Molecular, DNA Restriction Enzymes, Drug Resistance, Microbial, Protoplasts physiology, Rhizobium drug effects, Anti-Bacterial Agents pharmacology, DNA Transposable Elements, Escherichia coli genetics, Genes, Bacterial, Plant Tumors, Plants genetics, Plasmids, Rhizobium genetics
- Abstract
Chimeric bacterial genes conferring resistance to aminoglycoside antibiotics have been inserted into the Agrobacterium tumefaciens tumor-inducing (Ti) plasmid and introduced into plant cells by in vitro transformation techniques. The chimeric genes contain the nopaline synthase 5' and 3' regulatory regions joined to the genes for neomycin phosphotransferase type I or type II. The chimeric genes were cloned into an intermediate vector, pMON120, and inserted into pTiB6S3 by recombination and then introduced into petunia and tobacco cells by cocultivating A. tumefaciens cells with protoplast-derived cells. Southern hybridization was used to confirm the presence of the chimeric genes in the transformed plant tissues. Expression of the chimeric genes was determined by the ability of the transformed cells to proliferate on medium containing normally inhibitory levels of kanamycin (50 micrograms/ml) or other aminoglycoside antibiotics. Plant cells transformed by wild-type pTiB6S3 or derivatives carrying the bacterial neomycin phosphotransferase genes with their own promoters failed to grow under these conditions. The significance of these results for plant genetic engineering is discussed.
- Published
- 1983
- Full Text
- View/download PDF
27. Synthesis of the nutL DNA segments and analysis of antitermination and termination functions in coliphage lambda.
- Author
-
Drahos D, Galluppi GR, Caruthers M, and Szybalski W
- Subjects
- Base Sequence, DNA Restriction Enzymes, DNA, Bacterial genetics, Mutation, Oligodeoxyribonucleotides chemical synthesis, Phenotype, Plasmids, Bacteriophage lambda genetics, DNA, Viral genetics, Escherichia coli genetics, Transcription, Genetic
- Abstract
The nut antiterminator sequence, when present between a promoter and a terminator, permits the N-mediated antitermination of transcription in phage lambda. The efficiency of nutL was determined by assaying the activity of gene galK placed on a plasmid downstream from the promoter, nutL and terminator modules. As a reference and an estimate of the plasmid copy number, we have used an improved and very reproducible assay for bla activity. Sequences consisting of the 17-bp nutL core flanked by two HindIII cohesive sites were synthesized by the phosphite coupling method, and cloned in proper orientation between the Pp promoter of pBR322 and lambda gene N followed by the tL1 terminator on a galK-expression plasmid. The antitermination efficiencies for two synthetic 17-bp nutL sequences, one wild type and one point mutant at the base of the nutL stem, are similar but substantially reduced in comparison with the native 25-bp nutL sequence cloned at the same site in the otherwise identical galK-expression plasmid. Multiple tandem insertions of the synthetic 17-bp nutL segment successively increase antitermination efficiency, but also to levels below those of comparable plasmids carrying multiple copies of the native 25-bp nutL sequence. Thus, several specific base pairs in the flanking sequences appear to be important for the efficient nut function. In an inverted orientation the 17-bp nutL sequence has lost its antitermination function. It also lost the termination activity exhibited by inversion of the longer 25-bp and 74-bp native nutL sequences.
- Published
- 1982
- Full Text
- View/download PDF
28. Purification and sequence analysis of bioactive atrial peptides (atriopeptins).
- Author
-
Currie MG, Geller DM, Cole BR, Siegel NR, Fok KF, Adams SP, Eubanks SR, Galluppi GR, and Needleman P
- Subjects
- Amino Acid Sequence, Animals, Arginine analysis, Chromatography, High Pressure Liquid, Chromatography, Ion Exchange, Diuresis drug effects, Glycine analysis, Muscle Contraction drug effects, Muscle, Smooth drug effects, Muscle, Smooth, Vascular drug effects, Natriuresis drug effects, Peptides analysis, Peptides pharmacology, Phenylalanine analysis, Rats, Serine analysis, Heart Atria analysis, Peptides isolation & purification
- Abstract
Mammalian cardiac atria have several biologically active peptides that exert profound effects on sodium excretion, urine volume, and smooth muscle tone. In the present study two such peptides of low molecular weight were purified and separated from each other on the basis of differences in charge, hydrophobicity, and biological profile. The first peptide, designated atriopeptin I, exhibits natriuretic and diuretic activity and selectivity relaxes intestinal smooth muscle but not vascular smooth muscle strips. The second peptide, atriopeptin II, is a potent natriuretic and diuretic that relaxes both intestinal and vascular strips. Sequence analysis of atriopeptin I indicates that it is composed of 21 amino acids, of which serine and glycine residues predominate. The amino terminal sequence of atriopeptin II up to residue 21 is the same as that of atriopeptin I, with the addition of the Phe-Arg extension at the carboxyl terminus. Both peptides appear to be derived from a common high molecular weight precursor (designated atriopeptigen); their biological selectivity and potency may be determined by the site of carboxyl terminal cleavage.
- Published
- 1984
- Full Text
- View/download PDF
29. Transcription termination at lambda tR1 is mediated by interaction of rho with specific single-stranded domains near the 3' end of cro mRNA.
- Author
-
Chen CY, Galluppi GR, and Richardson JP
- Subjects
- Base Sequence, Chromosome Mapping, DNA-Directed RNA Polymerases metabolism, Gene Expression Regulation, Genes, Viral, Oligodeoxyribonucleotides pharmacology, RNA genetics, Repressor Proteins genetics, Rho Factor antagonists & inhibitors, Viral Proteins, Viral Regulatory and Accessory Proteins, Bacteriophage lambda genetics, DNA-Binding Proteins, RNA, Messenger genetics, Rho Factor physiology, Transcription Factors physiology, Transcription, Genetic
- Abstract
To determine whether E. coli rho protein mediates termination of transcription by interacting with specific segments of the nascent transcript, DNA oligonucleotides were used to sequester segments of phage lambda cro mRNA in hybrid helices. Formation of hybrids was demonstrated with RNAase H assays. Oligonucleotides complementary to either of two distinct, single-stranded sequences near the 3' end inhibited rho action at tR1, while oligonucleotides complementary to the sequence between those segments or to more 5' segments did not. The inhibitory oligonucleotides did not affect the elongation of cro mRNA or rho action on other transcripts. The results indicate that termination of transcription at tR1 is dependent upon contact of rho factor with specific, single-stranded domains near the 3' end of cro mRNA.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.